EBR Systems Raises AU$110M in Initial Public Offering on the Australian Securities Exchange (ASX)
Retrieved on:
星期二, 十一月 23, 2021
Health, Surgery, Cardiology, Medical Devices, Patient, EBR, Heart, Heart failure, News, Trial of the century, Coronary sinus, Bradycardia, CEO, Monash Medical Centre, Sale, Wise, Capital, Technology, CRT, Health care, ASX, Cardiology, ResMed, HESTA, Wireless, CSL, Royal Adelaide, Cardiac resynchronization therapy, Physician, AEDT, Life expectancy, Food and Drug Administration, Silicon, Appetite, Biotechnology, FDA, Australian Securities Exchange, Cochlear, Growth, Medical device, Pharmaceutical industry
Australian investors strong appetite for healthcare stock continues with the AU$110M listing of cardiovascular medical device company, EBR Systems, at 11am AEDT November 24 on the Australian Securities Exchange (ASX).
Key Points:
- Australian investors strong appetite for healthcare stock continues with the AU$110M listing of cardiovascular medical device company, EBR Systems, at 11am AEDT November 24 on the Australian Securities Exchange (ASX).
- Its been wonderful to see such strong investor support for EBRs initial public offering, said John McCutcheon, President and CEO of EBR Systems.
- In October, EBR successfully completed an AU$110M underwritten capital raise, which was strongly supported by new and existing institutional shareholders.
- Silicon Valley-based EBR Systems is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing.